• Stefan Lang, An Nulens, Edith Briot, Christian Kirisits, Marisol De Brabandere, Isabelle Dumas, Johannes Dimopoulos, Peter Petrow, Dietmar Georg, Erik Van Limbergen, Christine Haie-Meder, and Richard Pötter.
• Department of Radiotherapy and Radiobiology, Medical University of Vienna, Austria. stefan.lang@akhwien.at
• Radiother Oncol. 2006 Feb 1; 78 (2): 185-93.

PurposeTo perform a multicentre intercomparison study of treatment concepts for MRI assisted brachytherapy of cervix cancer based on recommendations of the Gynaecological GEC-ESTRO Working Group.MethodsEach participating centre (IGR Paris, University Hospital Leuven, Medical University of Vienna) contributed data of one patient with comparable clinical features. GTV, High Risk CTV (HR CTV), Intermediate Risk CTV (IR CTV) and organ walls of bladder, rectum and sigmoid colon were delineated at the time of each brachytherapy fraction on axial MR images with the applicator in place. Dose-volume histograms were calculated to evaluate doses to tumour, target volumes and organs at risk. Dose values were biologically normalised to equivalent doses in 2 Gy fractions (EQD(2), equivalent to 50 cGy/h low dose rate) applying the linear-quadratic model.ResultsTotal doses to point A from external beam therapy plus brachytherapy ranged from 85 to 91 Gy and were close to the dose covering 90% of HR CTV (D90=85-87 Gy). D90 of IR CTV was within 69-73 Gy. Doses to organs at risk were comparable.ConclusionsThis study indicates the feasibility of the GEC-ESTRO recommendations. Despite different treatment concepts, biologically normalised total doses to tumour, target volumes and organs at risk were comparable.

36 keywords...

hide…